NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free EDGE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.19▼$3.3050-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume445,770 shsAverage Volume373,201 shsMarket Capitalization$102.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Edge Therapeutics alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Edge Therapeutics Stock (NASDAQ:EDGE)PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. EDGE Stock News HeadlinesApril 24, 2024 | markets.businessinsider.comCutting-edge RM6 Million Laboratory Opens at UMMC to Advance Cancer TreatmentApril 23, 2024 | finance.yahoo.comRed Arrow Therapeutics Inc. closes $4.5M Seed Extension roundApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 22, 2024 | uk.finance.yahoo.comVect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and TumorsApril 22, 2024 | markets.businessinsider.comIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesApril 19, 2024 | finance.yahoo.comPeptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearchApril 18, 2024 | markets.businessinsider.comMaintaining the Edge: Argenx’s Hold Rating Amidst Rising Competition and Promising Therapy ResultsApril 18, 2024 | finance.yahoo.comPanasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing TechnologyApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 15, 2024 | finance.yahoo.comMyeloid Therapeutics to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 15, 2024 | finance.yahoo.comGastrointestinal Therapeutics and Diagnostics: Propelling Global Markets with Cutting-Edge Technologies by BCC Research LLCApril 14, 2024 | msn.comHow cutting-edge therapies—like Ozempic—are changing the drug-pricing landscapeApril 11, 2024 | msn.comPrelude Therapeutics Unveils Promising Cancer Treatment Advances at AACR MeetingApril 4, 2024 | seekingalpha.comBuy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia ManagementApril 4, 2024 | finance.yahoo.comMyeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACRApril 3, 2024 | benzinga.comUS Stocks Edge Lower; Private Employment Tops ViewsApril 3, 2024 | msn.comNeighbors on edge after dog owner dead blocks away from Washington Avenue: 'Honestly kind of scared'April 2, 2024 | finance.yahoo.comAccelerating New Molecule Discovery: Rakovina Therapeutics AI IntegrationApril 2, 2024 | sg.finance.yahoo.comUPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levelsApril 1, 2024 | marketwatch.comToronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell OrderApril 1, 2024 | finance.yahoo.comGPCR Therapeutics Announces Publication in PNAS Using Cutting Edge Spectroscopy to Detect GPCR Heteromers on Live Cancer CellsMarch 30, 2024 | seekingalpha.comCrispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In PlansMarch 28, 2024 | uk.finance.yahoo.comGlobal Metastatic Melanoma Therapeutics Market Anticipates Robust Growth with New Therapeutic DevelopmentsMarch 27, 2024 | finance.yahoo.comIs Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?March 27, 2024 | finance.yahoo.comCompanies Like Context Therapeutics (NASDAQ:CNTX) Could Be Quite RiskyMarch 22, 2024 | au.finance.yahoo.comQ4 2023 Mink Therapeutics Inc Earnings CallMarch 21, 2024 | finance.yahoo.comMirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated DiseasesSee More Headlines Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book3.42Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$102.41 million OptionableNot Optionable Beta3.65 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesFrank K. Bedu-AddoPresident, Chief Executive Officer & DirectorMichael P. KingChief Financial OfficerLauren WoodChief Medical OfficerGregory L. ConnChief Scientific OfficerJanetta TrochimiukControllerKey CompetitorsBarinthus BiotherapeuticsNASDAQ:BRNSCellectar BiosciencesNASDAQ:CLRBClearside BiomedicalNASDAQ:CLSDVaccitechNASDAQ:VACCAnixa BiosciencesNASDAQ:ANIXView All Competitors EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) announced its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Corbus Pharmaceuticals (CRBP), CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE). This page (NASDAQ:EDGE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
